CellSeed Of Japan Establishes French Subsidiary To Market Corneas
This article was originally published in PharmAsia News
Executive Summary
The Japanese bioventure CellSeed says it has set up a unit in France to serve the European market for the regenerative corneas it is developing. CellSeed, a spinoff of Tokyo Women's Medical University Hospital, has the corneas undergoing clinical trials in France. The products are to be used in transplants of cultured corneas. (Click here for more - a subscription may be required
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.